We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
Email registered. Please sign in.×
Enter your contact to build trust with supplier(s)×
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Indena is very well known as a leading API contract developer and supplier. Funded in Italy in 1921, the company is privately owned and serving the global markets with its 4 manufacturing plants. The technological offer covers APIs of botanical, fermentation and synthetic origin, with a unique expertise for HPAPIs. Capitalizing on its twenty year experience in handling HPAPIs development and manufacturing at large industrial scale, an additional new kilolab (LK2), designed to handle the production of highly toxic substances endowed with an OEL of 20 ng/m3 (including toxins for ADCs), was opened in 2018; given the market success, it is now undergoing capacity doubling . Additionally, Indena has opened in 2019 a pilot pharmaceutical plant featuring all the technologies available at Indena, to support clinical APIs and small commercial supplies, with a high degree of flexibility. Besides, a multipurpose fermentation suite (20 thousand liter capacity) is available with the possibility to handle toxic compounds. As far as Spray Drying is concerned, Indena has available two SDs working from organic solvents in the presence of excipients (a PSD2 was installed in 2019). A new smaller scale SD for HIPOs (with OEL ≥ 1 μg/m3) will be available in 2021. Indena is continuously investing in its CDMO offer.